Document Type
Article
Publication Date
1994
Abstract
Paclitaxel (Taxol®, Bristol-Meyers Squibb), anti neoplastic agent made from the bark of the Pacific yew tree, is undoubtedly one of the most exciting agents to be evaluated over the past decade. Paclitaxel has demonstrated significant promise against ovarian and metastatic breast cancer, and appears to be the most effective single agent to date for non-small-cell lung cancer in trials conducted by Eastern Cooperative Oncology Group (ECOG).
Recommended Citation
Wong, SF. "Outpatient Administration of Paclitaxel". California Journal of Hospital Pharmacists 1994: Vol 6 (7); 11-14.
Copyright
California Society of Health-System Pharmacists
Included in
Cancer Biology Commons, Natural Products Chemistry and Pharmacognosy Commons, Other Pharmacy and Pharmaceutical Sciences Commons
Comments
This article was originally published in California Journal of Hospital Pharmacists, volume 6, issue 7, in 1994.